NCT Cancer Prevention, Early Detection and Outcomes Program
The best way to fight cancer is to prevent it from developing at all. The NCT program area for Cancer Prevention, Early Detection and Outcomes uses novel epidemiologic and molecular techniques to investigate factors that determine cancer risk and cancer outcomes. The program develops new modalities for early detection and cancer prevention and evaluates population-wide programs for cancer screening.
The strategies employed in this research area focus on
- Identifying genetic, behavioral and environmental risk factors for cancer to develop tailored prevention strategies
- Conducting exposure and behavior intervention trials measuring specific biomarkers
- Evaluating physical activity, energy balance and metabolic syndrome in prevention, prognosis and treatment response
- Establishing and evaluating targeted smoking-cessation programs at NCT
- Developing new early-detection modalities in colorectal cancer, evaluate efficacy and cost-effectiveness
(1) a novel p16INK4a staining technique for HPV-related lesions (Reuschenbach Int J Cancer 2012; Ikenberg J Natl Cancer Inst. 2013). This CINtec plus test in global use was developed by mtm laboratories AG, acquired by Roche in 2011 (http://www.ventana.com/cervical). (2) familial risk of cancer (Kharazmi BMJ 2012), (3) TERT promoter mutations in sporadic melanoma (Horn Science 2013), (4) translocations may have a genetic basis (Weinhold Nature Genet 2013), (5) new genetic susceptibility loci for multiple myeloma (Chubb Nature Genet 2013), and (6) personalized prevention strategies based on inherited genetic characteristics (Coghill Gut 2011; Seufert Carcinogenesis 2013; Coghill Clin Canc Res 2011; Kraus Pharmacogen Genom 2013; Haug Genes Chrom Cancer 2012).